PolarisDMD: Phase 3 Clinical Trial of Edasalonexent, a Novel NF-kB Inhibitor (November 2018)

PPMD and Catabasis hosted a webinar on November 7, 2018 to discuss the Phase 3 PolarisDMD clinical trial studying edasalonexent in Duchenne muscular dystrophy, which is enrolling boys ages 4 to 7 (up to 8th birthday) regardless of mutation type who have not been on steroids for at least 6 months.